Charles Schwab
VTVT icon

Charles Schwab’s vTv Therapeutics VTVT Stock Holding History

Charles Schwab’s Portfolio VTVT Stock Details VTVT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-524
Closed -$60K – 3545
2021
Q1 		$60K Hold
524
– – ﹤0.01% 3421
2020
Q4 		$39K Hold
524
– – ﹤0.01% 3361
2020
Q3 		$38K Hold
524
– – ﹤0.01% 3293
2020
Q2 		$48K Buy
+524
New +$51.7K ﹤0.01% 3262
2018
Q2 		– Sell
-305
Closed -$50K – 3148
2018
Q1 		$50K Hold
305
– – ﹤0.01% 3065
2017
Q4 		$74K Buy
+305
New +$68.4K ﹤0.01% 3044

Other funds holding VTVT

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
HF
HRT Financial New York $40.1B AUM 58.22% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
WAG
Winthrop Advisory Group Boston, Massachusetts $1.48B AUM 22.62% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
CIM
CIM Investment Management Pittsburgh, Pennsylvania $375M AUM 32.03% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Charles Schwab's VTVT Position: Q2 2021 in Review

Charles Schwab sold out of vTv Therapeutics (VTVT) in Q2 2021, closing a stake of 524 shares — an estimated $60K sold.

Charles Schwab first reported a position in VTVT in Q4 2017 and held it in 6 quarters. The position peaked at $74K in Q4 2017. 42 funds tracked by Wall St. Rank hold VTVT as of Q2 2021.

  • Charles Schwab reported no remaining vTv Therapeutics position as of Q2 2021 after selling out during the quarter.
  • Charles Schwab sold 524 vTv Therapeutics shares in Q2 2021, an estimated $60K.
  • Charles Schwab first reported a position in vTv Therapeutics in Q4 2017 and held it in 6 quarters.
  • Charles Schwab's vTv Therapeutics position peaked at $74K in Q4 2017.
  • 42 funds tracked by Wall St. Rank held vTv Therapeutics as of Q2 2021.

Based on Charles Schwab's 13F filing for Q2 2021, filed 16 Aug 2021.